US FTC Continues Aggressive Scrutiny of Pharmaceutical Patents Listed in the Orange Book

On April 30, 2024, the US Federal Trade Commission (“FTC”) announced that it had sent “warning letters” to 10 branded pharmaceutical manufacturers, alleging that the companies had made “improper or inaccurate listing of patents” in the Food and Drug Administration’s (“FDA”) “Orange Book.”…
By: Mayer Brown